Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
523 total, page 11 of 11
Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00004073
Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome
NCT00003961
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
NCT00003751
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
NCT00004041
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
NCT00003802
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00003616
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
NCT00003572
UCN-01 in Treating Patients With Advanced Cancer
NCT00003289
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
NCT00011934
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00003960
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00003962
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
NCT00003176
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT00003561
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
NCT00003243
Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
NCT00003340
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
NCT00003414
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
NCT00002971
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
NCT00007813
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00003538
Penclomedine in Treating Patients With Advanced Solid Tumors
NCT00002915
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
NCT00004464
Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
NCT00002778
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
NCT00002600
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 210 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline
69 recruiting of 523 indexed (13% open); 301 completed (58%).
Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide
Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 523 trials (± recruiting share)
- AbbVie · 526 trials · 21% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 13% open enrollment (± trial volume)
- MetroHealth Medical Center · 13% recruiting · 76 trials
- Texas Tech University Health Sciences Center · 13% recruiting · 76 trials
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page
523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.
- 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.